IPOs

Elanco’s $1.7 billion IPO looks too pricey, and here’s why
Elanco’s $1.7 billion IPO looks too pricey, and here’s why
Marketwatch
Elanco
Eli Lilly
IPOs
animal health
spinoffs
Flag link:
Immuno-Oncology Players Gritstone And Sutro Join The Biotech IPO Frenzy
Immuno-Oncology Players Gritstone And Sutro Join The Biotech IPO Frenzy
Forbes
biotech
IPOs
immuno-oncology
Gritstone Oncology
Sutro BioPharma
Flag link:
Principia jumps after $106.3M IPO
Principia jumps after $106.3M IPO
BioCentury
Principia Biopharma
IPOs
Flag link:
Allogene Therapeutics Announces Filing For IPO
Allogene Therapeutics Announces Filing For IPO
CP Wire
Allogene
IPOs
CAR-T
Flag link:
Is Moderna prepping for biotech's biggest-ever IPO?
Is Moderna prepping for biotech's biggest-ever IPO?
Fierce Biotech
Moderna Therapeutics
IPOs
messenger RNA
Flag link:
Biotech IPOs are booming, but is the frenzy almost over?
Biotech IPOs are booming, but is the frenzy almost over?
San Francisco Chronicle, CA
biotech
IPOs
Flag link:
With anti-VEGF challenger in clinic, Kodiak files for IPO
With anti-VEGF challenger in clinic, Kodiak files for IPO
BioCentury
Kodiak Sciences
anti-VEGF
IPOs
Flag link:
Two more Peninsula IPOs tell the story of biotech's investment boom
Two more Peninsula IPOs tell the story of biotech's investment boom
Bizjournals.com
IPOs
Guardant Health
Kodiak Sciences
Flag link:
Liquid biopsy company Guardant files for NASDAQ IPO
Liquid biopsy company Guardant files for NASDAQ IPO
BioCentury
IPOs
Guardant Health
liquid biopsy
Flag link:
Working with Patients and a Fresh $80M, Fulcrum Eyes a 2019 IPO
Working with Patients and a Fresh $80M, Fulcrum Eyes a 2019 IPO
Xconomy
Fulcrum Therapeutics
IPOs
FSHD
Flag link:
Principia Sets IPO Terms as It Eyes Late-Stage Studies for Lead Drug
Principia Sets IPO Terms as It Eyes Late-Stage Studies for Lead Drug
Xconomy
Principia Biopharma
IPOs
Flag link:
Sutro Biopharma, Arvinas Are Latest to Tee Up Biotech IPOs
Sutro Biopharma, Arvinas Are Latest to Tee Up Biotech IPOs
Xconomy
biotech
IPOs
Sutro BioPharma
Arvinas
cancer
Flag link:
The booming Boston/Cambridge biotech hub claims an industry-leading role — nobody beats it at raising record amounts of money
The booming Boston/Cambridge biotech hub claims an industry-leading role — nobody beats it at raising record amounts of money
Endpoints
biotech
IPOs
Boston
Flag link:
Second time lucky? Alzheon tries for much-reduced IPO
Second time lucky? Alzheon tries for much-reduced IPO
Fierce Biotech
Alzheon
IPOs
Alzheimer's disease
tramiprosate
Flag link:
Y-mAbs Plans IPO to Advance Two Pediatric Cancer Drugs to the FDA
Y-mAbs Plans IPO to Advance Two Pediatric Cancer Drugs to the FDA
Xconomy
Y-mAbs
IPOs
pediatric cancer
FDA
neuroblastoma
Flag link:
AbbVie, Sanofi-backed Principia offers an $86M IPO after burning through $148M for pipeline work
AbbVie, Sanofi-backed Principia offers an $86M IPO after burning through $148M for pipeline work
Endpoints
IPOs
Principia Biopharma
Sanofi
AbbVie
PRN1008
autoimmune disease
Flag link:
AstraZeneca spinout Entasis files for $86M IPO to fund antibiotic phase 3
AstraZeneca spinout Entasis files for $86M IPO to fund antibiotic phase 3
Fierce Biotech
Entasis
IPOs
AstraZeneca
clinical trials
beta-lactams
Flag link:
Samumed, a $12 billion startup that wants to cure baldness and smooth out your wrinkles, just raised even more funding as it plots an IPO
Samumed, a $12 billion startup that wants to cure baldness and smooth out your wrinkles, just raised even more funding as it plots an IPO
Business Insider
Samumed
baldness
wrinkle treatment
IPOs
aesthetics
stem cells
Flag link:
The Week Ahead In Biotech: Conferences, PDUFA Dates And IPOs
The Week Ahead In Biotech: Conferences, PDUFA Dates And IPOs
Yahoo/Benzinga
biotech
IPOs
Pain Therapeutics
Remoxy
Vertex Pharmaceuticals
lumacaftor/ivacaftor
Alnylam
Patisiran
Regeneron
Eylea
Insmed
Paratek
Vaccinex
Flag link:
Elanco’s IPO Would Free Eli Lilly to Focus on Pharmaceuticals
Elanco’s IPO Would Free Eli Lilly to Focus on Pharmaceuticals
Xconomy
Elanco
Eli Lilly
animal health
IPOs
Flag link:

Pages